Literature DB >> 9219791

Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases.

D Heresbach1, M Alizadeh, A Dabadie, N Le Berre, J F Colombel, J Yaouanq, J F Bretagne, G Semana.   

Abstract

OBJECTIVE: Genetic susceptibility to inflammatory bowel disease is well recognized. There is also increasing evidence for the activation of the mucosal immune system and the production of inflammatory cytokines, i.e., interleukin (IL)-1ra and IL-1beta in the inflammatory bowel disease. The aim of this study was to analyze the IL-1beta and IL-1ra gene polymorphism and linkage disequilibrium coefficient between the different alleles of these genes in patients with Crohn's disease (CD) or ulcerative colitis (UC), according to the severity of the disease.
METHODS: Two hundred twenty-eight inflammatory bowel disease patients (87 UC and 141 CD) were included in this study and compared with 113 unrelated controls. The IL-1beta and IL-1ra gene polymorphism was studied after specific amplification of variable regions by PCR. A penta-allelic polymorphism, corresponding to a VNTR region located in intron 2 of the IL-1ra gene, was analyzed, whereas bi-allelic RFLPs displayed by two restriction enzymes (TaqI and AvaI) at position -511 of the IL-1beta gene were analyzed.
RESULTS: There was no significant difference of genotype distribution between controls and CD or UC patients. However, surgically treated UC patients were characterized by a higher frequency of genotype IL-1ra 1-2 (39 vs 16%, pc < 0.01) compared with nonoperated UC patients. Moreover, nonoperated UC patients displayed a lower frequency of IL-1ra allele 2 than surgically treated UC patients (14 vs 34%, pc < 0.002) or controls (14 vs 30%, pc < 0.005). Furthermore, simultaneous analysis of the IL-1beta and IL-1ra genes that are located in the same region of chromosome 2 revealed that CD patients carrying the IL-1beta allele 2 were more often noncarriers of IL-1ra allele 2 (p < 0.005). Moreover, UC and CD patients were, characterized by a lower frequency of the association of IL-1ra allele 2 and IL-1beta allele 2 compared with controls (8.3 vs 20.3% and 10.6 vs 20.3%, p < 0.03).
CONCLUSIONS: IL-1ra and IL-1beta gene polymorphism analysis from a clinical standpoint might help in defining UC prognosis. However, functional studies at both the circulating and mucosal level with stratification on allele associations, especially IL-1ra allele 2-IL-1beta allele 2 subgroups must be realized before therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219791

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  Multilocus linkage analysis of affected sib pairs.

Authors:  Iuliana Ionita; Shaw-Hwa Lo
Journal:  Hum Hered       Date:  2006-01-17       Impact factor: 0.444

2.  IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway.

Authors:  Rana Al-Sadi; Dongmei Ye; Hamid M Said; Thomas Y Ma
Journal:  Am J Pathol       Date:  2010-11       Impact factor: 4.307

3.  Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo.

Authors:  Rana Al-Sadi; Shuhong Guo; Karol Dokladny; Matthew A Smith; Dongmei Ye; Archana Kaza; D Martin Watterson; Thomas Y Ma
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

4.  Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians.

Authors:  M J Carter; F S di Giovine; S Jones; J Mee; N J Camp; A J Lobo; G W Duff
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease.

Authors:  David-G Cox; J-Bart-A Crusius; Petra-H-M Peeters; H-Bas Bueno-de-Mesquita; A-Salvador Pena; Federico Canzian
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

6.  Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental Shigellosis.

Authors:  J Arondel; M Singer; A Matsukawa; A Zychlinsky; P J Sansonetti
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy.

Authors:  F Conti; S Breton; F Batteux; V Furlan; D Houssin; B Weill; Y Calmus
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

8.  Polymorphisms of the IL-1beta and IL-1beta-inducible genes in ulcerative colitis.

Authors:  Hiroaki Nohara; Yuki Saito; Singo Higaki; Naoko Okayama; Yuichiro Hamanaka; Kiwamu Okita; Yuji Hinoda
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

9.  Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk.

Authors:  Yu He; XinJun Liang; ChunQing Meng; ZengWu Shao; Yong Gao; Qiang Wu; JianXiang Liu; Hong Wang; ShuHua Yang
Journal:  Int Orthop       Date:  2014-05-31       Impact factor: 3.075

10.  Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease.

Authors:  P C Stokkers; B E van Aken; N Basoski; P H Reitsma; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.